Athira grant application used doctor s credentials without his knowledge - Puget Sound Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
In Pancreatic Cancer, New Biomarker May Predict Benefit of Tumor-Penetrating Peptide
March 9, 2021
Hunkered behind a dense layer of fibrotic tissue, pancreatic tumors stubbornly resist the delivery of therapeutic molecules. Yet this barrier, this desmoplastic tumor tissue, can be penetrated by iRGD, a nine-amino-acid cyclic peptide. In experiments with models of pancreatic cancer, specifically, mouse models and organoids, iRGD was found to penetrate tumors via a molecular pathway mediated by β5 integrin, a protein that is produced by carcinoma-associated fibroblasts (CAFs). This newfound role for β5 integrin suggests that the protein may serve as a useful biomarker, one that could indicate which patients will respond best to therapies that combine iRGD and chemotherapeutic agents.
New tumor-penetrating therapy may improve outcomes in patients with pancreatic cancer
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.
The study, published online March 9, 2021 in
In Pancreatic Cancer, New Biomarker May Predict Benefit of Tumor-Penetrating Peptide genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Andrew Lowy, MD, is the co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores. view more
Credit: UC San Diego Health Sciences
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.